A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT05119335 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

120

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated as a result of Sponsor portfolio reprioritization.

Conditions

ccRCC
Clear Cell Renal Cell Carcinoma
Kidney Cancer
Kidney Neoplasms
Renal Cancer
Renal Neoplasms
Recurrent Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Refractory Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Hypoxia
Renal Cell Carcinoma
Hypoxia Inducible Factor (HIF)
HIF2α Inhibitor
Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
Hypoxia Inducible Factor 2α (HIF-2α)
Clear Cell

Interventions

DRUG: Oral NKT2152

Sponsor

NiKang Therapeutics, Inc.